Loading…

COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA

The fourth wave of COVID-19 pandemic peaked in the US at 160,000 daily cases, concentrated primarily in southern states. As the Delta variant has continued to spread, we evaluated the impact of accelerated vaccination on reducing hospitalization and deaths across northeastern and southern regions of...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Regional Health - Americas (Online) 2022-02, Vol.6, p.100147-100147, Article 100147
Main Authors: Vilches, Thomas N., Sah, Pratha, Moghadas, Seyed M., Shoukat, Affan, Fitzpatrick, Meagan C., Hotez, Peter J., Schneider, Eric C., Galvani, Alison P.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3
cites cdi_FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3
container_end_page 100147
container_issue
container_start_page 100147
container_title Lancet Regional Health - Americas (Online)
container_volume 6
creator Vilches, Thomas N.
Sah, Pratha
Moghadas, Seyed M.
Shoukat, Affan
Fitzpatrick, Meagan C.
Hotez, Peter J.
Schneider, Eric C.
Galvani, Alison P.
description The fourth wave of COVID-19 pandemic peaked in the US at 160,000 daily cases, concentrated primarily in southern states. As the Delta variant has continued to spread, we evaluated the impact of accelerated vaccination on reducing hospitalization and deaths across northeastern and southern regions of the US census divisions. We used an age-stratified agent-based model of COVID-19 to simulate outbreaks in all states within two U.S. regions. The model was calibrated using reported incidence in each state from October 1, 2020 to August 31, 2021, and parameterized with characteristics of the circulating SARS-CoV-2 variants and state-specific daily vaccination rate. We then projected the number of infections, hospitalizations, and deaths that would be averted between September 2021 and the end of March 2022 if the states increased their daily vaccination rate by 20 or 50% compared to maintaining the status quo pace observed during August 2021. A 50% increase in daily vaccine doses administered to previously unvaccinated individuals is projected to prevent a total of 30,727 hospitalizations and 11,937 deaths in the two regions between September 2021 and the end of March 2022. Southern states were projected to have a higher weighted average number of hospitalizations averted (18.8) and lives saved (8.3) per 100,000 population, compared to the weighted average of hospitalizations (12.4) and deaths (2.7) averted in northeastern states. On a per capita basis, a 50% increase in daily vaccinations is expected to avert the most hospitalizations in Kentucky (56.7 hospitalizations per 100,000 averted with 95% CrI: 45.56 - 69.9) and prevent the most deaths in Mississippi, (22.1 deaths per 100,000 population prevented with 95% CrI: 18.0 - 26.9). Accelerating progress to population-level immunity by raising the daily pace of vaccination would prevent substantial hospitalizations and deaths in the US, even in those states that have passed a Delta-driven peak in infections. This study was supported by The Commonwealth Fund. SMM acknowledges the support from the Canadian Institutes of Health Research [OV4 – 170643, COVID-19 Rapid Research] and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, MfPH grant. MCF acknowledges support from the National Institutes of Health (5 K01 AI141576).
doi_str_mv 10.1016/j.lana.2021.100147
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_827e8a29c16b4460a38a0ddd1b1343df</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2667193X21001435</els_id><doaj_id>oai_doaj_org_article_827e8a29c16b4460a38a0ddd1b1343df</doaj_id><sourcerecordid>2616280355</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3</originalsourceid><addsrcrecordid>eNp9Uk1vEzEQXSEQrUr_AAe0Ry4J_tq1V0JIVcpHpEo9QBE3a9aeTRxt7GA7keDO_8bJlqq9cPLMmzdvrJlXVa8pmVNC23eb-Qge5owwWgBChXxWnbO2lTPa8R_PH8Vn1WVKG0IIU5Jz0r2szrjopFRCnVd_Frffl9eFV69D2rkMo_sN2QWfavC2tgh5XcIDxoy23nuLsRRqMAZHjHAEDyVx_tRU72JYRdjWztc-xLxGSBmjP2mlsC9ASSKuTgPCUBegvvt69ap6McCY8PL-vajuPn38tvgyu7n9vFxc3cxMw2iesUbB0BNQTT9AwyxvO2Gl6Ringxy4wr7lSjWmw8ai4CgHQ62UBkraGez5RbWcdG2Ajd5Ft4X4Swdw-gSEuNIQszMjasUkKmCdoW0vREuAKyDWWtpTLrgditaHSWu377doDfocYXwi-rTi3VqvwkErSYVQXRF4ey8Qw889pqy3LpW1lrti2CfNWtoyRXjTFCqbqCaGlCIOD2Mo0Uc76I0-2kEf7aAnO5SmN48_-NDy7_iF8H4iYFn5wWHUyTj0Bq2LaHLZifuf_l9R-MmT</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616280355</pqid></control><display><type>article</type><title>COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Vilches, Thomas N. ; Sah, Pratha ; Moghadas, Seyed M. ; Shoukat, Affan ; Fitzpatrick, Meagan C. ; Hotez, Peter J. ; Schneider, Eric C. ; Galvani, Alison P.</creator><creatorcontrib>Vilches, Thomas N. ; Sah, Pratha ; Moghadas, Seyed M. ; Shoukat, Affan ; Fitzpatrick, Meagan C. ; Hotez, Peter J. ; Schneider, Eric C. ; Galvani, Alison P.</creatorcontrib><description>The fourth wave of COVID-19 pandemic peaked in the US at 160,000 daily cases, concentrated primarily in southern states. As the Delta variant has continued to spread, we evaluated the impact of accelerated vaccination on reducing hospitalization and deaths across northeastern and southern regions of the US census divisions. We used an age-stratified agent-based model of COVID-19 to simulate outbreaks in all states within two U.S. regions. The model was calibrated using reported incidence in each state from October 1, 2020 to August 31, 2021, and parameterized with characteristics of the circulating SARS-CoV-2 variants and state-specific daily vaccination rate. We then projected the number of infections, hospitalizations, and deaths that would be averted between September 2021 and the end of March 2022 if the states increased their daily vaccination rate by 20 or 50% compared to maintaining the status quo pace observed during August 2021. A 50% increase in daily vaccine doses administered to previously unvaccinated individuals is projected to prevent a total of 30,727 hospitalizations and 11,937 deaths in the two regions between September 2021 and the end of March 2022. Southern states were projected to have a higher weighted average number of hospitalizations averted (18.8) and lives saved (8.3) per 100,000 population, compared to the weighted average of hospitalizations (12.4) and deaths (2.7) averted in northeastern states. On a per capita basis, a 50% increase in daily vaccinations is expected to avert the most hospitalizations in Kentucky (56.7 hospitalizations per 100,000 averted with 95% CrI: 45.56 - 69.9) and prevent the most deaths in Mississippi, (22.1 deaths per 100,000 population prevented with 95% CrI: 18.0 - 26.9). Accelerating progress to population-level immunity by raising the daily pace of vaccination would prevent substantial hospitalizations and deaths in the US, even in those states that have passed a Delta-driven peak in infections. This study was supported by The Commonwealth Fund. SMM acknowledges the support from the Canadian Institutes of Health Research [OV4 – 170643, COVID-19 Rapid Research] and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, MfPH grant. MCF acknowledges support from the National Institutes of Health (5 K01 AI141576).</description><identifier>ISSN: 2667-193X</identifier><identifier>EISSN: 2667-193X</identifier><identifier>DOI: 10.1016/j.lana.2021.100147</identifier><identifier>PMID: 34977848</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Lancet Regional Health - Americas (Online), 2022-02, Vol.6, p.100147-100147, Article 100147</ispartof><rights>2021 The Authors</rights><rights>2021 The Authors.</rights><rights>2021 The Authors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3</citedby><cites>FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3</cites><orcidid>0000-0003-4414-0227 ; 0000-0002-1132-5084 ; 0000-0002-2059-6716</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714489/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2667193X21001435$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34977848$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vilches, Thomas N.</creatorcontrib><creatorcontrib>Sah, Pratha</creatorcontrib><creatorcontrib>Moghadas, Seyed M.</creatorcontrib><creatorcontrib>Shoukat, Affan</creatorcontrib><creatorcontrib>Fitzpatrick, Meagan C.</creatorcontrib><creatorcontrib>Hotez, Peter J.</creatorcontrib><creatorcontrib>Schneider, Eric C.</creatorcontrib><creatorcontrib>Galvani, Alison P.</creatorcontrib><title>COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA</title><title>Lancet Regional Health - Americas (Online)</title><addtitle>Lancet Reg Health Am</addtitle><description>The fourth wave of COVID-19 pandemic peaked in the US at 160,000 daily cases, concentrated primarily in southern states. As the Delta variant has continued to spread, we evaluated the impact of accelerated vaccination on reducing hospitalization and deaths across northeastern and southern regions of the US census divisions. We used an age-stratified agent-based model of COVID-19 to simulate outbreaks in all states within two U.S. regions. The model was calibrated using reported incidence in each state from October 1, 2020 to August 31, 2021, and parameterized with characteristics of the circulating SARS-CoV-2 variants and state-specific daily vaccination rate. We then projected the number of infections, hospitalizations, and deaths that would be averted between September 2021 and the end of March 2022 if the states increased their daily vaccination rate by 20 or 50% compared to maintaining the status quo pace observed during August 2021. A 50% increase in daily vaccine doses administered to previously unvaccinated individuals is projected to prevent a total of 30,727 hospitalizations and 11,937 deaths in the two regions between September 2021 and the end of March 2022. Southern states were projected to have a higher weighted average number of hospitalizations averted (18.8) and lives saved (8.3) per 100,000 population, compared to the weighted average of hospitalizations (12.4) and deaths (2.7) averted in northeastern states. On a per capita basis, a 50% increase in daily vaccinations is expected to avert the most hospitalizations in Kentucky (56.7 hospitalizations per 100,000 averted with 95% CrI: 45.56 - 69.9) and prevent the most deaths in Mississippi, (22.1 deaths per 100,000 population prevented with 95% CrI: 18.0 - 26.9). Accelerating progress to population-level immunity by raising the daily pace of vaccination would prevent substantial hospitalizations and deaths in the US, even in those states that have passed a Delta-driven peak in infections. This study was supported by The Commonwealth Fund. SMM acknowledges the support from the Canadian Institutes of Health Research [OV4 – 170643, COVID-19 Rapid Research] and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, MfPH grant. MCF acknowledges support from the National Institutes of Health (5 K01 AI141576).</description><issn>2667-193X</issn><issn>2667-193X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9Uk1vEzEQXSEQrUr_AAe0Ry4J_tq1V0JIVcpHpEo9QBE3a9aeTRxt7GA7keDO_8bJlqq9cPLMmzdvrJlXVa8pmVNC23eb-Qge5owwWgBChXxWnbO2lTPa8R_PH8Vn1WVKG0IIU5Jz0r2szrjopFRCnVd_Frffl9eFV69D2rkMo_sN2QWfavC2tgh5XcIDxoy23nuLsRRqMAZHjHAEDyVx_tRU72JYRdjWztc-xLxGSBmjP2mlsC9ASSKuTgPCUBegvvt69ap6McCY8PL-vajuPn38tvgyu7n9vFxc3cxMw2iesUbB0BNQTT9AwyxvO2Gl6Ringxy4wr7lSjWmw8ai4CgHQ62UBkraGez5RbWcdG2Ajd5Ft4X4Swdw-gSEuNIQszMjasUkKmCdoW0vREuAKyDWWtpTLrgditaHSWu377doDfocYXwi-rTi3VqvwkErSYVQXRF4ey8Qw889pqy3LpW1lrti2CfNWtoyRXjTFCqbqCaGlCIOD2Mo0Uc76I0-2kEf7aAnO5SmN48_-NDy7_iF8H4iYFn5wWHUyTj0Bq2LaHLZifuf_l9R-MmT</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Vilches, Thomas N.</creator><creator>Sah, Pratha</creator><creator>Moghadas, Seyed M.</creator><creator>Shoukat, Affan</creator><creator>Fitzpatrick, Meagan C.</creator><creator>Hotez, Peter J.</creator><creator>Schneider, Eric C.</creator><creator>Galvani, Alison P.</creator><general>Elsevier Ltd</general><general>The Authors. Published by Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4414-0227</orcidid><orcidid>https://orcid.org/0000-0002-1132-5084</orcidid><orcidid>https://orcid.org/0000-0002-2059-6716</orcidid></search><sort><creationdate>20220201</creationdate><title>COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA</title><author>Vilches, Thomas N. ; Sah, Pratha ; Moghadas, Seyed M. ; Shoukat, Affan ; Fitzpatrick, Meagan C. ; Hotez, Peter J. ; Schneider, Eric C. ; Galvani, Alison P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vilches, Thomas N.</creatorcontrib><creatorcontrib>Sah, Pratha</creatorcontrib><creatorcontrib>Moghadas, Seyed M.</creatorcontrib><creatorcontrib>Shoukat, Affan</creatorcontrib><creatorcontrib>Fitzpatrick, Meagan C.</creatorcontrib><creatorcontrib>Hotez, Peter J.</creatorcontrib><creatorcontrib>Schneider, Eric C.</creatorcontrib><creatorcontrib>Galvani, Alison P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Lancet Regional Health - Americas (Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vilches, Thomas N.</au><au>Sah, Pratha</au><au>Moghadas, Seyed M.</au><au>Shoukat, Affan</au><au>Fitzpatrick, Meagan C.</au><au>Hotez, Peter J.</au><au>Schneider, Eric C.</au><au>Galvani, Alison P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA</atitle><jtitle>Lancet Regional Health - Americas (Online)</jtitle><addtitle>Lancet Reg Health Am</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>6</volume><spage>100147</spage><epage>100147</epage><pages>100147-100147</pages><artnum>100147</artnum><issn>2667-193X</issn><eissn>2667-193X</eissn><abstract>The fourth wave of COVID-19 pandemic peaked in the US at 160,000 daily cases, concentrated primarily in southern states. As the Delta variant has continued to spread, we evaluated the impact of accelerated vaccination on reducing hospitalization and deaths across northeastern and southern regions of the US census divisions. We used an age-stratified agent-based model of COVID-19 to simulate outbreaks in all states within two U.S. regions. The model was calibrated using reported incidence in each state from October 1, 2020 to August 31, 2021, and parameterized with characteristics of the circulating SARS-CoV-2 variants and state-specific daily vaccination rate. We then projected the number of infections, hospitalizations, and deaths that would be averted between September 2021 and the end of March 2022 if the states increased their daily vaccination rate by 20 or 50% compared to maintaining the status quo pace observed during August 2021. A 50% increase in daily vaccine doses administered to previously unvaccinated individuals is projected to prevent a total of 30,727 hospitalizations and 11,937 deaths in the two regions between September 2021 and the end of March 2022. Southern states were projected to have a higher weighted average number of hospitalizations averted (18.8) and lives saved (8.3) per 100,000 population, compared to the weighted average of hospitalizations (12.4) and deaths (2.7) averted in northeastern states. On a per capita basis, a 50% increase in daily vaccinations is expected to avert the most hospitalizations in Kentucky (56.7 hospitalizations per 100,000 averted with 95% CrI: 45.56 - 69.9) and prevent the most deaths in Mississippi, (22.1 deaths per 100,000 population prevented with 95% CrI: 18.0 - 26.9). Accelerating progress to population-level immunity by raising the daily pace of vaccination would prevent substantial hospitalizations and deaths in the US, even in those states that have passed a Delta-driven peak in infections. This study was supported by The Commonwealth Fund. SMM acknowledges the support from the Canadian Institutes of Health Research [OV4 – 170643, COVID-19 Rapid Research] and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, MfPH grant. MCF acknowledges support from the National Institutes of Health (5 K01 AI141576).</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34977848</pmid><doi>10.1016/j.lana.2021.100147</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4414-0227</orcidid><orcidid>https://orcid.org/0000-0002-1132-5084</orcidid><orcidid>https://orcid.org/0000-0002-2059-6716</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2667-193X
ispartof Lancet Regional Health - Americas (Online), 2022-02, Vol.6, p.100147-100147, Article 100147
issn 2667-193X
2667-193X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_827e8a29c16b4460a38a0ddd1b1343df
source ScienceDirect Journals; PubMed Central
title COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A26%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20hospitalizations%20and%20deaths%20averted%20under%20an%20accelerated%20vaccination%20program%20in%20northeastern%20and%20southern%20regions%20of%20the%20USA&rft.jtitle=Lancet%20Regional%20Health%20-%20Americas%20(Online)&rft.au=Vilches,%20Thomas%20N.&rft.date=2022-02-01&rft.volume=6&rft.spage=100147&rft.epage=100147&rft.pages=100147-100147&rft.artnum=100147&rft.issn=2667-193X&rft.eissn=2667-193X&rft_id=info:doi/10.1016/j.lana.2021.100147&rft_dat=%3Cproquest_doaj_%3E2616280355%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-258afb0a85bfa52d3694d7c9231f7f38eb63885c9e5de43e7fc1d77ca5de9ceb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2616280355&rft_id=info:pmid/34977848&rfr_iscdi=true